NCT05620628 2026-01-21Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)Samsung Medical CenterPhase 2 Recruiting25 enrolled
NCT03228667 2026-01-14QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsImmunityBio, Inc.Phase 2 Active not recruiting40 enrolled